The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription - PubMed (original) (raw)
. 2012 Apr 15;72(8):1929-34.
doi: 10.1158/0008-5472.CAN-11-3589. Epub 2012 Feb 14.
Affiliations
- PMID: 22337994
- DOI: 10.1158/0008-5472.CAN-11-3589
The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription
Anthony B Mak et al. Cancer Res. 2012.
Abstract
The AC133 epitope has been used as a marker for both normal and cancer stem cells from multiple tissue lineages. To identify transcription factors that regulate CD133 expression, we conducted parallel large-scale RNA interference screens in Caco-2 cancer cells that endogenously express CD133 and in engineered HEK293 cells that express CD133 from a heterologous promoter. The transcription factor AF4 was identified following a comparative analysis between the two screens. We then showed that AF4 is a promoter of CD133 transcription in multiple cancer cell lines. Knockdown of AF4 resulted in a dramatic reduction in CD133 transcript levels. Importantly, a subset of pediatric acute lymphoblastic leukemias (ALL) harbor a fusion oncogene results from a chromosomal translocation that juxtaposes the mixed-lineage leukemia (MLL) gene and the AF4 gene. An investigation of the functional role of CD133 in the MLL-AF4-dependent ALL cells revealed that CD133 was required for leukemia cell survival. Together, our findings show AF4-dependent regulation of CD133 expression, which is required for the growth of ALL cells. CD133 may therefore represent a therapeutic target in a subset of cancers.
Similar articles
- AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3.
Ahmad K, Scholz B, Capelo R, Schweighöfer I, Kahnt AS, Marschalek R, Steinhilber D. Ahmad K, et al. Oncotarget. 2015 Sep 22;6(28):25784-800. doi: 10.18632/oncotarget.4703. Oncotarget. 2015. PMID: 26329759 Free PMC article. - The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.
Bursen A, Schwabe K, Rüster B, Henschler R, Ruthardt M, Dingermann T, Marschalek R. Bursen A, et al. Blood. 2010 Apr 29;115(17):3570-9. doi: 10.1182/blood-2009-06-229542. Epub 2010 Mar 1. Blood. 2010. PMID: 20194896 - The heterodimerization domains of MLL-FYRN and FYRC--are potential target structures in t(4;11) leukemia.
Pless B, Oehm C, Knauer S, Stauber RH, Dingermann T, Marschalek R. Pless B, et al. Leukemia. 2011 Apr;25(4):663-70. doi: 10.1038/leu.2010.308. Epub 2011 Jan 14. Leukemia. 2011. PMID: 21233834 - The molecular functions of common and atypical MLL fusion protein complexes.
Takahashi S, Yokoyama A. Takahashi S, et al. Biochim Biophys Acta Gene Regul Mech. 2020 Jul;1863(7):194548. doi: 10.1016/j.bbagrm.2020.194548. Epub 2020 Apr 19. Biochim Biophys Acta Gene Regul Mech. 2020. PMID: 32320750 Review. - Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.
Sanjuan-Pla A, Bueno C, Prieto C, Acha P, Stam RW, Marschalek R, Menéndez P. Sanjuan-Pla A, et al. Blood. 2015 Dec 17;126(25):2676-85. doi: 10.1182/blood-2015-09-667378. Epub 2015 Oct 13. Blood. 2015. PMID: 26463423 Free PMC article. Review.
Cited by
- Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia.
Schneider P, Crump NT, Arentsen-Peters STCJM, Smith AL, Hagelaar R, Adriaanse FRS, Bos RS, de Jong A, Nierkens S, Koopmans B, Milne TA, Pieters R, Stam RW. Schneider P, et al. Exp Hematol Oncol. 2023 Sep 22;12(1):81. doi: 10.1186/s40164-023-00445-8. Exp Hematol Oncol. 2023. PMID: 37740239 Free PMC article. - The Biological Significance of AFF4: Promoting Transcription Elongation, Osteogenic Differentiation and Tumor Progression.
Long Q, Xiang M, Xiao L, Wang J, Guan X, Liu J, Liao C. Long Q, et al. Comb Chem High Throughput Screen. 2024;27(10):1403-1412. doi: 10.2174/0113862073241079230920082056. Comb Chem High Throughput Screen. 2024. PMID: 37815186 Review. - CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity.
Bueno C, Velasco-Hernandez T, Gutiérrez-Agüera F, Zanetti SR, Baroni ML, Sánchez-Martínez D, Molina O, Closa A, Agraz-Doblás A, Marín P, Eyras E, Varela I, Menéndez P. Bueno C, et al. Leukemia. 2019 Aug;33(8):2090-2125. doi: 10.1038/s41375-019-0418-8. Epub 2019 Feb 18. Leukemia. 2019. PMID: 30778134 Free PMC article. No abstract available. - An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia.
Riegg F, Lutz MS, Schmied BJ, Heitmann JS, Queudeville M, Lang P, Jung G, Salih HR, Märklin M. Riegg F, et al. Cancers (Basel). 2021 Apr 1;13(7):1632. doi: 10.3390/cancers13071632. Cancers (Basel). 2021. PMID: 33915811 Free PMC article. - CD133/prominin-1-mediated autophagy and glucose uptake beneficial for hepatoma cell survival.
Chen H, Luo Z, Dong L, Tan Y, Yang J, Feng G, Wu M, Li Z, Wang H. Chen H, et al. PLoS One. 2013;8(2):e56878. doi: 10.1371/journal.pone.0056878. Epub 2013 Feb 20. PLoS One. 2013. PMID: 23437259 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials